ERLOTINIB IN METASTATIC, EGFR WILD-TYPE, NON-SMALL CELL LUNG CANCER (NSCLC) AS SECOND OR FURTHER LINE OF THERAPY

被引：0
|
作者：
Hernandez, Alba [1 ]
Calera, Lourdes [1 ]
Alvarez, Maria [1 ]
Hernando, Jorge [1 ]
Torres, Irene [1 ]
Pajares, Isabel [1 ]
Madani, Julia [1 ]
Cebollero, Ana [1 ]
Anton-Torres, Antonio [1 ]
Artal, Angel [1 ]
机构：
[1] Hosp Univ Miguel Servet, Zaragoza, Spain
来源：
JOURNAL OF THORACIC ONCOLOGY | 2013年 / 8卷
关键词：
erlotinib; second line; wild-type EGFR;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2.24-036
引用
收藏
页码：S1017 / S1017
页数：1
相关论文
共 50 条
  • [11] EGFR tyrosine kinase inhibitor in advanced non-small cell lung cancer with wild-type EGFR
    Wang, Z.
    Wu, Y. L.
    Yang, J.
    Wang, B.
    Huang, Y.
    Zhou, Q.
    Xu, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [12] Approval Summary: Erlotinib Maintenance Therapy of Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
    Cohen, Martin H.
    Johnson, John R.
    Chattopadhyay, Somesh
    Tang, Shenghui
    Justice, Robert
    Sridhara, Rajeshwari
    Pazdur, Richard
    ONCOLOGIST, 2010, 15 (12): : 1344 - 1351
  • [13] ERLOTINIB in Second Line Treatment of Metastatic Lung Cancer: About 20 Case of Non-Small Cell LUNG
    Teyar, Nahla
    Bensaou, Malika Gamaz
    Bouzid, Kamel
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1498 - S1499
  • [14] Absence of TTF-1 Immunoreactivity Can Predict EGFR Wild-Type in Non-Small Cell Lung Cancer (NSCLC)
    Bosdet, I.
    Young, S. S.
    Ali, R. H.
    McNeil, B. K.
    Wong, C.
    Garbutt, K.
    Karsan, A.
    Ionescu, D. N.
    MODERN PATHOLOGY, 2012, 25 : 474A - 474A
  • [15] A study of EGFR wild-type non-small cell lung cancer ALK genetic mutation
    Wang, Shoufeng
    Mao, Naiquan
    Zuo, Chuantian
    Pan, Hong
    Xie, Tong
    Huang, Yaoyuan
    Pan, Qi
    Wu, Junwei
    TRANSLATIONAL CANCER RESEARCH, 2017, 6 (05) : 976 - 980
  • [16] Gene-expression profiles predict sorafenib efficacy in wild-type EGFR non-small cell lung cancer (NSCLC)
    Saintigny, Pierre
    Blumenschein, George R.
    Diao, Lixia
    Wang, Jing
    Coombes, Kevin
    Liu, Suyu
    Kim, Edward
    Tsao, Anne
    Herbst, Roy
    Alden, Christine
    Lee, Jack J.
    Tang, Ximing
    Stewart, David
    Kies, Merrill
    Fossella, Frank
    Tran, Hai
    Mao, Li
    Hicks, Marshall
    Erasmus, Jeremy
    Gupta, Sanjay
    Girard, Luc
    Peyton, Michael
    Davis, Suzanne
    Lippman, Scott
    Hong, Waun Ki
    Minna, John
    Wistuba, Ignacio
    Heymach, John
    CANCER RESEARCH, 2012, 72
  • [17] Absence of TTF-1 Immunoreactivity Can Predict EGFR Wild-Type in Non-Small Cell Lung Cancer (NSCLC)
    Bosdet, I.
    Young, S. S.
    Ali, R. H.
    McNeil, B. K.
    Wong, C.
    Garbutt, K.
    Karsan, A.
    Ionescu, D. N.
    LABORATORY INVESTIGATION, 2012, 92 : 474A - 474A
  • [18] Examination of the importance of RUNX category in EGFR wild-type non-small cell lung cancer
    Kobayakawa, Atsushi
    Takeda, Kanako
    Masuda, Tatuya
    Yanagida, Yohei
    Obi, Natsuno
    Sakuramoto, Naoya
    Hada, Asuka
    Horiuchi, Ayaka
    Takeda, Mizuho
    Sasaki, Asami
    Matsuo, Hidemasa
    Sugiyama, Hiroshi
    Adachi, Souichi
    Kamikubo, Yasuhiko
    CANCER SCIENCE, 2021, 112 : 445 - 445
  • [19] A phase II trial of erlotinib monotherapy for pretreated elderly patients with advanced EGFR wild-type non-small cell lung cancer Cancer
    Minemura H.
    Yokouchi H.
    Azuma K.
    Hirai K.-I.
    Sekine S.
    Oshima K.
    Kanazawa K.
    Tanino Y.
    Inokoshi Y.
    Ishii T.
    Katsuura Y.
    Oishi A.
    Ishida T.
    Munakata M.
    BMC Research Notes, 8 (1)
  • [20] SECOND LINE ERLOTINIB IN NON-SMALL CELL LUNG CANCER: A LOCAL EXPERIENCE
    Smith, C. F.
    Garcia-Alonso, Angel
    Drury, G.
    Gostage, A.
    Smith, N.
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1180 - S1181
12345